Singapore markets closed
  • Straits Times Index

    3,260.03
    -11.54 (-0.35%)
     
  • S&P 500

    4,349.93
    -6.52 (-0.15%)
     
  • Dow

    34,168.09
    -129.61 (-0.38%)
     
  • Nasdaq

    13,542.12
    +2.82 (+0.02%)
     
  • BTC-USD

    36,688.42
    -1,280.59 (-3.37%)
     
  • CMC Crypto 200

    836.38
    -19.43 (-2.27%)
     
  • FTSE 100

    7,501.60
    +31.82 (+0.43%)
     
  • Gold

    1,808.30
    -21.40 (-1.17%)
     
  • Crude Oil

    87.55
    +0.20 (+0.23%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • Nikkei

    26,170.30
    -841.03 (-3.11%)
     
  • Hang Seng

    23,807.00
    -482.90 (-1.99%)
     
  • FTSE Bursa Malaysia

    1,515.99
    +0.23 (+0.02%)
     
  • Jakarta Composite Index

    6,611.16
    +10.34 (+0.16%)
     
  • PSE Index

    7,273.52
    +19.91 (+0.27%)
     

VGI Health Technology Limited (VTL.NSX) partners with ENDRA Life Sciences in NAFLD/NASH Phase II Clinical Study

·3-min read
VGI Health Technology Limited
VGI Health Technology Limited

VGI Health Technology Limited (VTL.NSX) partners with ENDRA Life Sciences in NAFLD/NASH Phase II Clinical Study

Sydney, Australia, Nov 29, 2021 - (ABN Newswire) - VGI Health Technology Limited (NSX:VTL), a clinical-stage biotechnology company wth delivery platforms for improving the bioavailability and efficacy of tocotrienols (a natural product which is one part of vitamin E) and ENDRA Life Sciences Inc. (NAS:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS(R)), announced today the signing of a collaboration agreement between VGI's wholly-owned subsidiary Invictus Ops Pty Ltd and Endra to incorporate TAEUS as an add-on technology to support VGI's patient screening and biomarker measurement during the upcoming Phase II clinical study on Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (NAFLD/NASH) of IVB001.

"We are delighted to partner with VGI to help advance the clinical development of IVB001. It's clear that pharmaceutical companies and contract research organizations driving the NAFLD/NASH therapy pipeline face the same hepatic steatosis measurement challenges using MRI and liver biopsy as end-user clinicians. By adding ENDRA's cost-effective, non-invasive TAEUS technology to VGI's protocol, we expect to deliver time and cost savings for the study through simpler, faster and non-invasive biomarker measurements of liver fat," commented ENDRA's Chairman and Chief Executive Officer Francois Michelon. "In addition, we are excited to have the opportunity to expand and strengthen our global presence into Australia, which provides further opportunity to educate care providers and patients alike regarding the importance of both detection and treatment of this condition."

"VGI is excited to incorporate ENDRA's technology into screening for our Phase II study of IVB001, which targets NAFLD/NASH," said VGI's Chief Executive Officer and Managing Director Dr Glenn Tong. "After extensive discussions between Endra and VGI, we have come to the view that there is enormous potential value in capturing data on the degree of hepatic steatosis (the build up of fat in the liver) and other biomarkers to refine our understanding of systemic variables associated with NAFLD/NASH. We believe ENDRA's TAEUS system is uniquely designed to accomplish this task for us. VGI's focus on innovation, leads us naturally to explore new technologies like ENDRA's TAEUS that can lead to efficiencies in execution of our clinical studies," concluded Dr Tong.

In September 2015, a Phase Ia clinical study on IVB001 had positive topline data where all primary endpoints were achieved, including: confirmation of the bioavailability of the compound, with good plasma levels, dose relationship and duration of plasma levels achieved. Research from a number of groups using orally-delivered tocotrienols to treat NAFLD/NASH have shown promising results in improving liver function and bringing about favourable histological changes in NAFLD/NASH and this points to transmucosally delivered tocotrienols like VGI's IVB001 having great potential to address this intractable disease where there is no approved treatment.

About VGI Health Technology Limited:


VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

Contact:

Glenn Tong
CEO and Managing Director
Ph: +61 (0) 412 193 350

Andrew Crook
Investor and Media Relations
Ph:+61 (0) 419 788 431

Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200

Source:
VGI Health Technology Limited

Copyright (C) 2021 ABN Newswire. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting